Immunicum AB
-
2002
Company Description
Immunicum reports preliminary immunological data from the ongoing clinical phase II-study in mRCC
Immunicum AB (publ), a clinical phase II company, develops cancer immunotherapies. The Company’s two main groups of therapeutic cancer vaccines, in addition to the method for expansion of tumor-specific T-cells, are based on many years of research within the area of transplantation immunology.
-
Manufacturer:
Science and Engineering -
Formed:
2002 -
Company Website:
-
Company E-mail:
-
Company Address:
Grafiska vägen 2, SE-412 63GothenburgSweden -
We recognize our sponsors starting at $1 per entry.
Learn more at https://www.ithistory.org/benefits